Marion Ferri, Federica Zotta, Roberta Donadelli, Claire Dossier, Charlotte Duneton, Carine El-Sissy, Véronique Fremeau-Bacchi, Thérésa Kwon, Lisa Quadri, Andrea Pasini, Anne-Laure Sellier-Leclerc, Marina Vivarelli, Julien Hogan
BACKGROUND: Between 5 and 50% of atypical hemolytic uremic syndrome (aHUS) cases in children are caused by autoantibodies against complement factor H (CFH). Given the acquired autoimmune nature of the disease, plasma exchange (PE) and various immunosuppressive treatments have been used. More recently, eculizumab has been proposed. METHODS: In this multicenter, retrospective study, we report outcomes of 12 children with anti-FH antibody-associated HUS treated with eculizumab associated with various immunosuppressive regimens...
April 17, 2024: Pediatric Nephrology